Physician profile
Christopher E Cannon
NPI 1487650586
$7,194.59
in general payments reported to CMS, 2019-2025
29 companies · $44.80 in 2025
The $44.80 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,055 · 2020: $628 · 2021: $1,454 · 2022: $888 · 2023: $603 · 2024: $523 · 2025: $44.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $1,301.36 | 2019-2020 | |
| Medtronic, INC. | $1,164.30 | 2021-2025 | Hawkone, Linq II |
| Medical Device Business Services, INC. | $1,063.09 | 2019 | |
| Medtronic Vascular, INC. | $524.09 | 2019-2020 | |
| Abbott Laboratories | $454.33 | 2019-2024 | Mitraclip |
| Janssen Pharmaceuticals, INC | $406.79 | 2019-2023 | Xarelto |
| Pfizer INC. | $325.93 | 2019-2024 | |
| Heartflow, INC. | $272.19 | 2022-2025 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $224.46 | 2019-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $202.43 | 2019-2023 | |
| Boston Scientific Corporation | $184.43 | 2019-2024 | Varithena Administration Pack, Watchman Access System |
| Philips North America LLC | $175.39 | 2019-2024 | (Ck4) Mcot |
| Novartis Pharmaceuticals Corporation | $150.54 | 2019-2024 | |
| Amgen INC. | $124.24 | 2022-2024 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $100.26 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.40 | 2019-2023 | Jardiance |
| Cardiovascular Systems INC. | $64.13 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $54.65 | 2022-2023 | Verquvo |
| Lundbeck LLC | $52.26 | 2019-2020 | |
| Angiodynamics, INC. | $51.64 | 2024 | Venacure 1470 Pro |
| Actelion Pharmaceuticals US, INC. | $48.16 | 2019 | |
| Esperion Therapeutics, INC. | $36.43 | 2023 | Nexletol |
| Cardiva Medical, INC. | $29.91 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.78 | 2021-2022 | |
| Novo Nordisk INC | $23.76 | 2024 | Rybelsus, Ozempic |
| Biosense Webster, INC. | $21.33 | 2021 | |
| Inspire Medical Systems, INC. | $16.61 | 2024 | Inspire |
| Inari Medical, INC. | $14.69 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Regeneron Healthcare Solutions, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.